Molecular classification of gastric cancer

doi:10.3760/cma.j.issn.1673422X.2017.03.017

Abstract

Abstract: Gastric cancer has high heterogeneity, and the traditional histopathologic classification has a limited significance for clinical work. Along with the dramatic development of molecular detection technology, it may be much more helpful for the treatment and prognosis to use the molecular classifications. Recently, there have been many researches on the molecular classification of gastric cancer, such as Tan type, Lei type, clonality type, The Cancer Genome Atlas (TCGA) type, Asian Cancer Research Group (ACRG) type, and so on. All of these molecular classification methods have respective advantages and disadvantages.

Key words: Stomach neoplasms, Molecular classification

Wang Bingzhi, Xue Liyan, Lyu Ning. Molecular classification of gastric cancer[J]. Journal of International Oncology, 2017, 44(3): 224-227.

References

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J ］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［2］ Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update［J］. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 16-27. DOI: 10.1158/10559965.EPI150578. ［3］ Shen J, Wei J, Wang H, et al. A threegene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer［J］. J Transl Med, 2013, 11: 73. DOI: 10.1186/147958761173. ［4］ Jeong SH, Han JH, Kim JH, et al. Bax predicts outcome in gastric cancer patients treated with 5fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy［J］. Dig Dis Sci, 2011, 56(1): 131-138. DOI: 10.1007/s1062001012808. ［5］ Qiu M, Zhou Y, Zhang X, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients［J］. BMC Cancer, 2014, 14: 823. DOI: 10.1186/1471240714823. ［6］ Tan IB, Ivanova T, Lim KH, et al. Intrinsic subtypes of gastric can cer, based on gene expression pattern, predict survival and respond differently to chemotherapy［J］. Gastroenterology, 2011, 141(2): 476-485, 485.e111. DOI: 10.1053/j.gastro.2011.04.042. ［7］ Lee HJ, Nam KT, Park HS, et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer［J］. Gastroenterology, 2010, 139(1): 213-225.e3. DOI: 10.1053/j.gastro.2010.04.008. ［8］ Wang J, Yu JC, Kang WM, et al. The predictive effect of cadherin17 on lymph node micrometastasis in pN0 gastric cancer［J］. Ann Surg Oncol, 2012, 19(5): 1529-1534. DOI: 10.1245/s1043401121153. ［9］ Wang J, Kang WM, Yu JC, et al. Cadherin17 induces tumorigenesis and lymphatic metastasis in gastric cancer through activation of NFκB signaling pathway［J］. Cancer Biol Ther, 2013, 14(3): 262270. DOI: 10.4161/cbt.23299. ［10］ Choong ML, Tan SH, Tan TZ, et al. Molecular integrative clustering of Asian gastric cell lines revealed two distinct chemosensitivity clusters ［J］. PLoS One, 2014, 9(10): e111146. DOI: 10.1371/journal.pone.0111146. ［11］ Chen K, Yang D, Li X, et al. Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy［J］. Proc Natl Acad Sci USA, 2015, 112(4): 1107-1112. DOI: 10.1073/pnas.1422640112. ［12］ Lei Z, Tan IB, Das K, et al. Identification of molecular subtypes of gastric cancer with different responses to PI3kinase inhibitors and 5fluorouracil［J］. Gastroenterology, 2013, 145(3): 554-565. DOI: 10.1053/j.gastro.2013.05.010. ［13］ Bass AJ, Thorsson V, Shmulevich I, et al. Comprehensive molecular characterization of gastric adenocarcinoma［J］. Nature, 2014, 513(7517): 202-209. DOI: 10.1038/nature13480. ［14］ Lee J, Van Hummelen P, Go C, et al. Highthroughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma［J］. PLoS One, 2012, 7(6): e38892. DOI: 10.1371/journal.pone.0038892. ［15］ Sukawa Y, Yamamoto H, Nosho K, et al. Alterations in the human epidermal growth factor receptor 2phosphatidylinositol 3kinasevAkt pathway in gastric cancer［J］. World J Gastroenterol, 2012, 18(45): 6577- 6586. DOI: 10.3748/wjg.v18.i45.6577. ［16］ Sawada T, Yashiro M, Sentani K, et al. New molecular staging with G factor supplements TNM classification in gastric cancer: a multicenter collaborative research by the Japan Society for Gastroenterological Carcinogenesis GProject committee［J］. Gastric Cancer, 2015, 18(1): 119 -128. DOI: 10.1007/s1012001403382 ［17］ Cristescu R, Lee J, Nebozhyn M, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes［J］. Nat Med, 2015, 21(5): 449-456. DOI: 10.1038/nm.3850 ［18］ Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer［J］. Nat Genet, 2011, 43(12): 1219-1223. DOI: 10.1038/ng.982 ［19］ Li Y, Li A, Glas M, et al. cMet signaling induces a reprogramming network and supports the glioblastoma stemlike phenotype［J］. Proc Natl Acad Sci USA, 2011, 108(24): 99519956. DOI: 10.1073/pnas.1016912108. ［20］ Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer［J］. Oncogene, 2010, 29(34): 4741-4751. DOI: 10.1038/onc.2010.215. ［21］ Loboda A, Nebozhyn MV, Watters JW, et al. EMT is the dominant program in human colon cancer［J］. BMC Med Genomics, 2011, 4: 9. DOI: 10.1186/1755879449. ［22］ Pino MS, Kikuchi H, Zeng M, et al. Epithelial to mesenchymal transition is impaired in colon cancer cells with microsatellite instability［J］. Gastroenterology, 2010, 138(4): 1406-1417. DOI: 10.1053/j.gastro.2009.12.010. ［23］ Roepman P, Schlicker A, Tabernero J, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelialtomesenchymal transition［J］. Int J Cancer, 2014, 134 (3): 552-562. DOI: 10.1002/ijc.28387. ［24］ Cho JY, Lim JY, Cheong JH, et al. Gene expression signaturebased prognostic risk score in gastric cancer［J］. Clin Cancer Res, 2011, 17(7): 1850-1857. DOI: 10.1158/10780432.CCR102180. ［25］ Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and cooccurrence among distinct therapeutic targets［J］. Gut, 2012, 61(5): 673-684. DOI: 10.1136/gutjnl2011301839. ［26］ Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis［J］. Lancet Oncol, 2010, 11(2): 136-146. DOI: 10.1016/S14702045(09)703432.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[3]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[4]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[5]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[6]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[7]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[8]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[9]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[10]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.
[11]	Deng Lili, Duan Xingyu, Li Baozhong. Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma [J]. Journal of International Oncology, 2023, 50(12): 751-757.
[12]	Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan. Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer [J]. Journal of International Oncology, 2023, 50(11): 677-682.
[13]	Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei. Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(10): 631-635.
[14]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali. Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer [J]. Journal of International Oncology, 2022, 49(5): 276-281.
[15]	Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun. Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer [J]. Journal of International Oncology, 2022, 49(12): 724-728.